Richard Mason

Richard Mason has had a long and varied career in the medical and business worlds. Richard began their career as a hospital physician in the UK's National Health Service, before moving into the business world with a series of increasingly senior positions in various companies. These positions included CEO of XO1 Limited, Head of Business Development and Strategy at BTG, and Executive-in-Residence at Advent Venture Partners. In 2015, they became Head of Johnson & Johnson Innovation, EMEA.

In 2018, they left Johnson & Johnson to become CEO of Divide & Conquer, a biotechnology start-up targeting tunneling nanotubules in cancer, with initial focus on glioblastoma. The company was funded by VC firm Medicxi. Unfortunately, the company was forced to close its doors in December 2019 due to lack of funding.

Mason then returned to the UK government in April 2020 to help with the country's response to the COVID-19 pandemic. Richard served as a member of the Vaccines Task Force and was involved in the distribution of vaccines across the country. Richard left the government in December 2020 to take up their current position as CEO of Apollo Therapeutics.

Richard Mason's educational career includes studying MBBS (Hons) at St Barthomew's Hospital Medical College, University of London, as well as an MBA at the University of Cambridge. Richard also holds a BSc (Hons) in Immunology from UCL, and has certification from the Royal College of Physicians in MRCP (UK) and the General Medical Council in Medical Registration.

Some direct reports include Sanjay Aggarwal - Chief Medical Officer, Jamie Heath - CFO, and Arjun Krishnan - Chief Business Officer.